|A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.|
|Jump to Full Text|
|PMID: 22289787 Owner: NLM Status: MEDLINE|
|Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common malignant neoplasm and more than 50% of patients succumb to this disease. HNSCCs are characterized by therapy resistance, which relies on the overexpression of anti-apoptotic proteins and on the aberrant regulation of the epidermal growth factor receptor (EGFR). As inherent and acquired resistance to therapy counteracts improvement of long-term survival, novel multi-targeting strategies triggering cancer cell death are urgently required. We investigated how induction of replicational stress by the ribonucleotide reductase inhibitor hydroxyurea (HU) combined with histone deacetylase inhibitors (HDACi) exerts anti-tumor activity. We treated HNSCC cell lines and freshly isolated tumor cells with HDACi, such as the clinically approved anti-epileptic drug valproic acid (VPA), in combination with HU. Our data demonstrate that at clinically achievable levels VPA/HU combinations efficiently block proliferation as well as clonogenic survival, and trigger apoptosis of HNSCC cells. In the presence of VPA/HU, such tumor cells increase expression of the pro-apoptotic BCL-2 family protein BIM, independent of wild-type p53 signaling and in the absence of increased expression of the p53 targets PUMA and BAX. The pro-apoptotic activity of BIM in HNSCCs was found critical for tumor cell death; ectopic overexpression of BIM induced HNSCC apoptosis and RNAi-mediated depletion of BIM protected HNSCC cells from VPA/HU. Also, significantly elevated BIM levels (p less than 0.01) were detectable in the apoptotic tumor centers versus proliferating tumor margins in HNSCC patients (n=31), underlining BIM's clinical relevance. Importantly, VPA/HU treatment additionally reduces expression and cell surface localization of EGFR. Accordingly, in a xenograft mouse model, VPA/HU efficiently blocked tumor growth (P less than 0.001) correlating with BIM induction and EGFR downregulation. We provide a molecular rationale for the potent anti-cancer activities of this drug combination. Our data suggest its exploitation as a potential strategy for the treatment of HNSCC and other tumor entities characterized by therapy resistance linked to dysregulated EGFR activation.|
|Roland H Stauber; Shirley K Knauer; Negusse Habtemichael; Carolin Bier; Britta Unruhe; Simona Weisheit; Stephanie Spange; Frank Nonnenmacher; Verena Fetz; Torsten Ginter; Sigrid Reichardt; Claus Liebmann; Günter Schneider; Oliver H Krämer|
Related Documents :
|22870217 - Identification of cbx3 and abca5 as putative biomarkers for tumor stem cells in osteosa...
22384017 - Disparate impact of butyroyloxymethyl diethylphosphate (an-7), a histone deacetylase in...
22775397 - 6-trifluoromethylpyridoxine: novel (19)f nmr ph indicator for in vivo detection.
22811257 - Laparoscopic posterior retroperitoneal adrenalectomy.
16272947 - Treatment of glomus jugulare tumors in patients with advanced age: planned limited surg...
10962447 - Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodie...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Oncotarget Volume: 3 ISSN: 1949-2553 ISO Abbreviation: Oncotarget Publication Date: 2012 Jan|
|Created Date: 2012-02-10 Completed Date: 2012-07-02 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101532965 Medline TA: Oncotarget Country: United States|
|Languages: eng Pagination: 31-43 Citation Subset: IM|
|Molecular and Cellular Oncology/Mainz Screening Center, University Hospital of Mainz, Germany. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Apoptosis / drug effects*, genetics
Apoptosis Regulatory Proteins / genetics, metabolism, physiology*
Carcinoma, Squamous Cell / drug therapy*, pathology
Cell Line, Tumor
Down-Regulation / drug effects
Enzyme Inhibitors / administration & dosage*, pharmacology
Gene Expression Regulation, Neoplastic / drug effects
Genes, erbB-1 / drug effects*
Head and Neck Neoplasms / drug therapy*, pathology
Histone Deacetylase Inhibitors / administration & dosage, pharmacology
Membrane Proteins / genetics, metabolism, physiology*
Mice, Inbred C57BL
Proto-Oncogene Proteins / genetics, metabolism, physiology*
Ribonucleotide Reductases / antagonists & inhibitors
Xenograft Model Antitumor Assays
|0/Apoptosis Regulatory Proteins; 0/Bcl-2-like protein 11; 0/Enzyme Inhibitors; 0/Histone Deacetylase Inhibitors; 0/Membrane Proteins; 0/Proto-Oncogene Proteins; EC 1.17.4.-/Ribonucleotide Reductases|
Journal ID (nlm-ta): Oncotarget
Journal ID (publisher-id): ImpactJ
Publisher: Impact Journals LLC
Copyright: © 2012 Stauber et al.
Received Day: 16 Month: 1 Year: 2011
Accepted Day: 25 Month: 1 Year: 2011
collection publication date: Month: 1 Year: 2012
Electronic publication date: Day: 28 Month: 1 Year: 2011
Volume: 3 Issue: 1
First Page: 31 Last Page: 43
PubMed Id: 22289787
|A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer|
|Roland H. Stauber1|
|Shirley K. Knauer2|
|Oliver H. Krämer3|
1 Molecular and Cellular Oncology/Mainz Screening Center, University Hospital of Mainz, Germany
2 Institute for Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, Germany
3 Institute of Biochemistry and Biophysics/Center for Molecular Biomedicine, Friedrich-Schiller-University Jena, Germany
4 Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Germany
5 II. Medizinische Klinik, Technische Universität München, Germany
|Correspondence: Correspondence to: Oliver H. Krämer, email@example.com
Correspondence: Roland H. Stauber, firstname.lastname@example.org
Correspondence: Shirley K. Knauer, email@example.com
With a worldwide annual incidence of more than 640,000 cases, head and neck cancer is the sixth most common malignant neoplasm in humans [1, 2]. The majority of head and neck squamous cell carcinoma (HNSCC) is induced by chronic exposure to a surplus of carcinogens enclosed in all forms of tobacco, synergized by heavy alcohol consumptions and/or is associated with oncogenic human papillomaviruses [3, 4]. HNSCC is characterized by local tumor aggressiveness, high rate of early recurrences and development of second primary carcinomas . Loco-regional relapse after therapy is the major cause of death despite modern disease management strategies [5, 6]. Hence, long-term survival rates, especially for advanced HNSCC (30-40%), have not improved significantly over the last decades [3, 6]. Currently, EGFR-targeting agents, such as antibodies or tyrosine kinase inhibitors gained major clinical attention [3, 7]. Despite encouraging developments, EGFR-directed therapies are effective only in a relatively small percentage of cancer patients underlining the need for additional combination treatment options [7-9].
Therapy resistance favoring recurring or advanced-stage HNSCC mainly results from failure of the tumor cells to undergo chemoradiation-induced apoptosis [1, 3]. Particularly, the intrinsic or mitochondrial pathway of programmed cell death (PCD) plays an important role for killing cancer cells in response to various therapies, and is controlled by interactions among pro- and anti-apoptotic BCL-2 protein family members [10, 11]. Pro-survival proteins like BCL-XL and BCL-2 inhibit apoptosis by binding and neutralizing the activities of the pro-apoptotic multidomain proteins BAX and BAK as well as the BH3 domain-only proteins BIM, BIK, NOXA, and PUMA [10-12].
Overexpression of anti-apoptotic BCL-2 proteins and apoptosis inhibitors like Survivin plays a critical role for therapy resistance and overall survival in HNSCC [10, 11, 13]. Consequently, strategies for neutralizing these cytoprotective factors involve shifting the cellular balance of anti- versus pro-apoptotic proteins in favor of the latter [10, 11, 13].
In this respect, histone deacetylase inhibitors (HDACi), such as VPA, have emerged as promising chemotherapeutic agents by inducing a wide range of anti-tumoral activities, including induction of cell cycle arrest and apoptosis [14-20]. HDACi can correct aberrant genomic and non-genomic signaling by chromatin remodeling as well as histone/protein modifications . Likewise, the ribonucleotide reductase inhibitor hydroxyurea (HU) sensitizes tumors to cancer therapy-induced apoptosis and has been used to treat HNSCC, particularly as part of chemoradiation platforms [22, 23]. However, it has not been investigated whether the combination of HDACi and HU may be applicable for the treatment of HNSCC nor have molecular mechanisms underlying its potential anti-tumoral activity been resolved.
Our study demonstrates for the first time that this drug combination efficiently eliminates HNSCC cancer cells by evoking expression of the pro-apoptotic protein BIM (B cell lymphoma 2 interacting mediator of cell death) and by downregulation of EGFR. This potent dual anti-tumoral activity suggests the clinical exploitation of this novel drug combination as a strategy to counteract therapy resistance in HNSCC.
Cell lines representing HNSCC from different anatomical sites (Supplementary Table SI) were treated with VPA and HU alone and in combination. MTT assays revealed that although VPA and HU individually inhibited proliferation in a dose-dependent manner, co-administration of VPA/HU was most effective (Figure 1A and B; Supplementary Table SI). Similar results were obtained using a clonogenic cell survival assay (Figure 1C). FACS analysis showed that the VPA/HU combination potently induced apoptosis and confirmed that HU induced S-phase arrest (Figure 2A; Supplementary Figure S1A). Induction of cell death was already evident using a single dosage of VPA/HU (0.5 mM/0.3 mM) and was not dependent on repetitive drug administration (Figure 2A). VPA/HU-induced apoptosis was further confirmed by independent experimental approaches. Immunoblot analysis showed enhanced cleavage of Caspases-3, -8 and -9 (Figure 2B; Supplementary Figure S1B). Also, increased Caspase-3 activity was detectable in lysates from treated cells, which could be counteracted by the pan-Caspase inhibitor Z-VAD-FMK (Figure 2B). The observed cleavage of Caspase-9, the loss of mitochondrial integrity, and DNA fragmentation upon treatment strongly imply that the intrinsic apoptosis pathway is responsible for VPA/HU induced cell death (Figure 2C; Supplementary Figure S1C). Similar results were obtained for several HNSCC cell lines tested and this effect was not restricted to VPA as treatment with other HU/HDACi combinations, such as TSA or butyrate, also resulted in cell death (Supplementary Table SI; Supplementary Figure S1D; data not shown).
When analyzing the effects of VPA/HU treatment on the levels of pro- and anti-apoptotic BCL-2 proteins, we observed increased BIM levels (Figure 3A). Although both drugs slightly induced expression of BIM, the effect was most prominent using the VPA/HU combination, correlating with enhanced apoptosis. The doses required to induce appreciable Caspase-3 activation and apoptosis were comparable to those necessary to induce BIM expression (Figure 2 and 3A). Notably, this effect was not restricted to VPA as treatment with other HU/HDACi combinations, such as with TSA or butyrate, also resulted in BIM induction and cell death (Supplementary Figure S1D; data not shown). Another BH-3-only protein, p53-upregulated modulator of apoptosis (PUMA), was recently reported to mediate apoptosis induced by EGFR inhibitors in HNSCC cells . In contrast to the strong induction of BIM by VPA/HU, immunoblot analysis revealed no enhanced expression of PUMA, BAX, and BCL-2/BCL-xL (Figure 3G and data not shown). Moreover, VPA/HU could induce BIM in p53-negative PC3 cells, and BIM induction could be verified by independent methods in p53-mutant FaDu cells (Supplementary Figure S1E, S2A).
To demonstrate that enhancing BIM levels triggers apoptosis in HNSCC cell lines, we first performed ectopic overexpression studies. Transfection of plasmids encoding a BIMEL-GFP fusion or untagged BIMEL, the longest BIM isoform (196 amino acids), resulted in efficient cell death (Figure 3B and not shown).
In order to further confirm the direct relevance of BIM for HDACi/HU-induced apoptosis, we used RNAi to deplete endogenous BIM. HNSCC cells with RNAi-mediated attenuated BIM expression displayed enhanced proliferation linked to reduced basal apoptosis rates (Figure 3C and data not shown). Furthermore, compared to the scrambled control, these cell lines showed significantly enhanced resistance to VPA/HU-induced cell death, as verified by analyzing Caspase-3 activation, TUNEL-staining and loss of mitochondrial integrity (Figure 3D; Supplementary Figure S2B). Similar results were observed for TSA or butyrate (data not shown). Collectively, these results provide strong evidence that BIM is critical for the HDACi/HU-induced killing of cancer cells.
Increased BIM levels (Figure 3E) could be the result of transcriptional activation [11, 24]. Transfection of a BIM promoter-containing luciferase reporter revealed that VPA/HU indeed stimulated BIM transcription (Figure 3F). Of note, this was observed in cells bearing inactive p53 (FaDu) as well as in p53-negative cells (PC3) (Supplementary Figure S1D and E). Experimental data collected with E2F- or c-JUN/FOS (AP1)-dependent reporter constructs transfected into HNSCC cells suggest a role of AP1 for the VPA/HU-mediated transcriptional activation of BIM (Supplementary Figure S2D). A BIM reporter containing an inactivated MYB-binding site was still responsive to treatment (Supplementary Figure S2C). Although the pharmacological inhibition of ERK signaling was critical for BIM expression in B-RAF/K-RAS mutant lung tumor cells , VPA/HU did not affect ERK levels but still evoked enhanced BIM expression in our cell models (Supplementary Figure S2E).
To underline the pathophysiological relevance of BIM not only for tumor cell models but also for the clinics, we first visualized BIM expression by IHC in tumor biopsies (n=31). Using the immunoreactive score (IRS) , significantly elevated BIM levels (p<0.001) were observed in cancer cells in the apoptotic tumor centers versus proliferating tumor margins (Figure 4A and 4B). Second, to definitely demonstrate that BIM is induced by VPA/HU also in primary tumor cells, we used cancer cells freshly isolated from HNSCC patients. Treatment of such tumor cells with VPA/HU resulted in enhanced BIM levels and cancer cell death (Figure 4C). Hence, regulated BIM expression appears to be relevant for disease progression and can be modulated by drug treatment.
The EGFR is overexpressed in various epithelial malignancies and also represses BIM expression [11, 26]. As EGFR-targeting strategies are intensively tested in the clinics, we investigated the effects of VPA/HU treatment on this receptor. Interestingly, immunoblot analysis revealed that the combination of VPA/HU efficiently reduced the levels of total and phosphorylated EGFR (Figure 5A). To further examine the intracellular localization of EGFR, cells were treated with VPA/HU or PBS, and examined by IHC analysis. This analysis not only confirmed the reduction of overall EGFR levels, but also showed that such treatment affected the cell surface localization of the receptor and additionally enhanced BIM expression (Figure 5C). As a control, VPA/HU treatment appears not to cause an unspecific degeneration of pro-survival proteins, as STAT3 levels, an important factor for head and neck carcinogenesis  or the growth factor receptor ERB-B2, were not significantly affected (Figure 5B; Supplementary Figure S2E). Collectively, these data provide evidence for a hitherto unknown molecular mechanism contributing to the potent anti-cancer activity of the VPA/HU combination. However, we cannot completely exclude the possibility that additional effects of VPA/HU on other proteins may at least partially contribute to the potent anti-tumoral activity of this drug combination.
Prior to testing the anti-tumoral activity of VPA/HU in murine models, we first compared the cell killing activity of VPA/HU and of chemotherapeutic drugs currently used in the clinics. In our HNSCC cell culture models and at the concentrations used, VPA/HU treatment was more effective in triggering cell death, when compared to the EGFR inhibitors cetuximab and gefitinib or the DNA-damaging agent cisplatin (Supplementary Figure S2F). Notably, interference with EGFR signaling by gefitinib also induced BIM expression (Supplementary Figure S2G).
These in vitro-results encouraged us to examine whether VPA/HU treatment also inhibits tumor growth in vivo. Using a xenograft model, established FaDu tumors were treated with VPA/HU (350 mg/kg, 750 mg/kg body weight) or PBS control i.p. for 14 days. Administration of VPA/HU to FaDu tumor-bearing mice significantly inhibited tumor growth (p<0.001) (Figure 5D). To visualize whether drug treatment also enhanced BIM levels and caused EGFR attenuation in vivo, tumors from treated and control animals were analyzed by IHC. Enhanced BIM levels and reduced EGFR expression were observed in tumors from VPA/HU treated animals compared to those from control mice (Figure 5E). The above data not only confirmed the potent anti-cancer activity of the VPA/HU combination in vivo, but also demonstrated the in vivo-relevance of the molecular mechanisms identified in our cell culture models. Of note, drug treatment of non-transplanted nude mice did not result in loss of body weight, and no organ damage was evident by histological inspection of treated C57BL/6 mice (data not shown). Hence, the anti-tumoral effect of our drug combination was not mediated by unspecific cytotoxicity.
Rational combination therapies are considered as the most efficient strategy to combat cancer [9, 28]. As the success of these treatments requires a profound molecular knowledge of their underlying mechanisms [29-31], we here studied the combination of two drugs, which have been suggested to affect tumor cell death by different mechanisms [23, 32, 33]. Employing comprehensive cell culture and in vivo models we here demonstrate for the first time that combining HDACi with HU potently kills HNSCC by a dual mechanism. Although such agents have been shown to individually affect tumor cells [22, 32], the (pre)clinical anti-tumor activities of the HDACi/HU combinations as well as the underlying molecular mechanisms have not been resolved so far for HNSCC.
Treatment of malignant cells with HDACi can induce a wide range of anticancer effects including apoptosis, cell cycle arrest and differentiation [15, 18, 20, 34, 35]. Numerous HDACi have been tested in the clinics or are currently the subject of ongoing early-phase clinical trials, including HNSCC [14, 19, 36-38]. Since HDACi monotherapies seem not to be effective against solid tumors, their full therapeutic potential will be best realized through combination with other anticancer agents [17, 19, 34]. However, most reports do not provide a well-defined molecular rationale for combining an HDACi with a given agent. Moreover, the molecular events underlying cooperative combination effects are often still to be identified [17, 19, 34].
In contrast, we here provide convincing evidence that activation of the proapoptotic BH3-only protein BIM together with EGFR attenuation are key regulators for VPA/HU-induced tumor cell death. This conclusion is based on several lines of evidence: First, HDACi/HU induced BIM upregulation, induction of apoptosis and loss of the clonogenic potential of HNSCC cell lines derived from different anatomical sites. This finding will be clinically relevant as SCC from different anatomical regions, like the hypopharynx or the oral cavity, differ in their clinical prognosis and response , but do express BIM as shown by the analysis of tumor biopsies. Currently, the clinical relevance of results obtained in permanent tumor cell lines are questioned, as such cell lines may differ from primary tumor cells at their molecular level . However, also freshly isolated tumor cells but not fibroblasts from HNSCC patients responded to VPA/HU administered at therapeutically achievable levels (0.5-1.5 mM) with BIM induction, EGFR downregulation and apoptosis. Several clinical studies have already demonstrated that VPA or HU plasma levels in the 0.5-1.5 mM range can be achieved in cancer patients without major toxicity [37, 40, 41], supporting an expectable clinical efficacy of the VPA/HU combination. Second, ectopic expression and RNAi experiments convincingly demonstrate that BIM is the BCL-2 family member essential for VPA/HU-induced cancer cell death. Third, VPA/HU efficiently prevented progression of HNSCC tumors in nude mice correlating with enhanced BIM levels and attenuation of EGFR surface expression. The tumor growth delay achieved with the combination treatment was highly significant compared with the untreated control, without major toxicity.
BIM-evoked apoptosis was found crucial for epithelial tumor cell death triggered by anti-cancer therapeutics [11, 42, 43]. We found that especially the VPA/HU combination cooperatively activated BIM at the transcriptional level. To date, several transcription factors, including p53, E2F, c-JUN/FOS (AP1), MYB, RUNX3, and FOXO3A have been reported to regulate BIM transcription [11, 24, 44]. Our data suggest that transcriptional activation of BIM in HNSCC by VPA/HU is mediated via AP1, which is not subject to mutation in oral cancer patients . It is possible that HU-mediated S-phase-dependent induction of c-JUN enhances BIM expression . Also, the activity of c-JUN is repressed by the HDAC3-NCoR complex , which is particularly sensitive to inhibition by VPA . Phosphorylation of c-JUN by JUN kinase (JNK) permits dissociation of HDAC3 and c-JUN-dependent transcription . HU has been shown to activate JNK in vivo , which may contribute to c-JUN-dependent BIM induction.
Although the BH-3-only protein PUMA was recently reported to mediate apoptosis of HNSCC cell lines induced by EGFR tyrosine kinase inhibitors , VPA/HU-mediated PCD did not require induction of the p53 targets PUMA and BAX. This finding seems to be of clinical relevance as VPA/HU-induced cell death does not rely on p53, which is mutated in the majority of HNSCC . Moreover, HNSCC cells with attenuated BIM expression displayed enhanced proliferation. Our finding that lowering this endogenous pro-apoptotic factors not only increases tumor cell survival but also proliferation might be involved in HNSCC therapy response and disease progression. Although BIM plays a major role in death signaling, this does not rule out the additional participation of other BCL-2 family members and/or other apoptosis inhibitor proteins [12, 50].
As we did not observe increased BCL-2/BCL-xL levels upon VPA/HU treatment potentially neutralizing increased BIM expression, it is conceivable to speculate that the addition of BH3 mimetics, such as ABT-737, may not further boost tumor cell death. Killing of B-RAF mutant lung tumor cells with ABT-737 required BIM induction by inhibition of ERK signaling. Furthermore, B-RAF wild type cancer cells were even largely resistant to this treatment . As the frequency of RAF/RAS mutations in HNSCC is rather low [52, 53], VPA/HU is hence likely to be clinically more effective when compared to certain other attempts to alter BCL-2 family members . It will furthermore be interesting to analyze the putative impact of VPA/HU on other molecules important for HNSCC survival. These are for example Aurora kinase-A, which shares signaling pathways with EGFR , and the structural protein NSP 5a3a promoting HNSCC apoptosis via the p53-related factor p73 [29, 30].
HNSCC tumors are often characterized by deregulated EGFR signaling due to receptor overexpression, activating receptor mutations and aberrant downstream signaling cascades . Survival is secured by the activation of MEK and ERK kinases, leading to stabilization of MCL-1, activation of BCL-2, and degradation of BIM . (Pre)clinical approaches interfering with EGFR signaling trigger apoptosis by also enhancing BIM expression [7, 11; this study]. Importantly, we show that VPA/HU treatment efficiently reduced not only EGFR levels and signaling, but also attenuated EGFR cell surface localization in cell and xenograft models. Although recent antibody-based EGFR targeting strategies have gained major attention, the clinical response rates to such therapies are rather low. In addition, the mechanism(s) conferring resistance of HNSCC against agents targeting the EGFR are ill-defined [8, 9], and the required agents are expensive and often show a suboptimal pharmacodynamic profile. VPA and HU are stable lower-cost drugs, which can be administered orally [14, 22, 33]. Moreover, the VPA/HU combination may represent a contingency treatment option for patients acquiring resistance to other EGFR-targeting approaches [8, 23, 54, 55]. Both, HU and VPA target major and general cellular survival factors that are misregulated in a variety of human cancers. E.g., cell cycle control is lost in the vast majority of malignancies, and HDACs are frequently overexpressed during tumorigenesis . The molecular mechanisms underlying EGFR attenuation upon exposure of malignant cells to VPA/HU in vitro and in mice remain to be resolved in detail. These may involve HU-induced replication arrest, known to affect oncogenic tyrosine kinase signaling , and/or the E3 ubiquitin ligase c-CBL, which controls EGFR ubiquitination and lysosomal degradation .
A major advantage allowing to expedite potential clinical studies employing VPA/HU for the treatment of HNSCC is the fact that both agents are FDA approved drugs. Albeit hardly in combination, both are used frequently in the clinic [17, 22, 37]. Thus, one can rely on an extensive knowledge on the therapeutically most effective dose and pharmacodynamics of these agents [32, 38]. Also, dose-limiting but clinically manageable side effects are known, including myelosuppression, fatigue, nausea, and diarrhea [22, 32, 33, 37, 38]. In contrast, neither toxicity profiles nor clinical efficacy are known for other anti-tumor strategies targeting BCL-2 family members .
Our study has several potential limitations. One is the use of immunocompromised mice as preclinical models of human malignancies, which do not always reflect the heterogeneity and complexity seen in patients. Second, although significantly higher concentrations of VPA or HU were previously used in tumor models without major signs of toxicity [58-60], the VPA/HU doses employed in the xenograft model exceed VPA/HU concentrations currently used in patients [22, 40]. However, cell culture results suggest that even low VPA/HU concentrations will show anti-tumoral efficacy in vivo. The minimal effective dose, the optimal application route (oral, i.p., i.v.), as well as the effects of long-term treatment needs to be determined in comprehensive preclinical studies prior to prospective clinical trials.
In conclusion, in addition to current chemo-radiotherapy platforms combining HU with HDACi might prove as an extra treatment option for HNSCC. Although not examined in this study, such drug combinations may be of therapeutic interest also for other tumor entities characterized by therapy resistance and EGFR overexpression, such as colon cancer.
Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors' institutional review board.
Cultivation of the indicated head and neck cancer and other tumor cell lines has been described in detail [25, 61-64] (Supplementary Table SI). Cell lines constitutively expressing shRNA directed against BIM or a scrambled control were generated by transfection of pHR-THT-BIMshRNA-SFFV-eGFP or pHR-THT-scr_shRNA-SFFV-eGFP , respectively. Cells were transfected using PEI (Sigma Aldrich, Munich, Germany) or Lipofectamine (Invitrogen, Karlsruhe, Germany) and selected by addition of puromycin (1 μg/ml; Sigma Aldrich, Munich, Germany). Luciferase reporter assays were carried out in triplicate and repeated thrice as stated .
Observation, image analysis and quantification of protein localization were performed as described . DNA/cell nuclei were visualized by Hoechst 33258 staining (Sigma Aldrich, Munich, Germany) as described before . At least 100 fluorescent cells were analyzed in three independent experiments.
Biopsies of patients diagnosed with HNSCC and treated at the Departments of Oral and Maxillofacial Surgery and ENT of the University Hospitals in Frankfurt and Mainz were analyzed. Tumor specimens were collected from primary tumors of patients who underwent surgery. All cases were clinically and histologically diagnosed according to established criteria including grading and TNM-classification (Supplementary Table SII). Studies of human tissue biopsies were performed according to the requirements of the local ethics committee (#83756604), and informed consent has been obtained in accordance with the Declaration of Helsinki. For the isolation of primary cancer cells, tumor specimens were cut into small pieces and enzymatically digested with collagenase typeI/hyaluronidase (Sigma Aldrich, Munich, Germany) in RPMI-1640 (Invitrogen, Karlsruhe, Germany) at 37°C overnight. Following digestion, dissociated cells were passed through a cell strainer, and epithelial cancer cells and fibroblast were isolated by MACS® separation using CD326 (EpCAM) or α-fibroblast MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's recommendations. Cells were propagated for one week as described  and subjected to analysis.
Cells were treated with VPA, trichostatin A (T), sodium butyrate (B), HU, or cisplatin (Sigma Aldrich, Munich, Germany) as described [16, 67]. The EGFR antagonists gefitinib (Tocris Bioscience, Ellisville, USA) and cetuximab (ImClone, New York, NY, USA) were applied for 48 h. For colony formation assays, 1×103 cells/T25 flask were seeded in triplicate. 24 h later, cells were treated with the indicated compounds or PBS control and further cultivated for 10 days. Drug-containing medium was replaced every day. Cells were fixed and stained with Giemsa. Colonies containing >50 cells were counted automatically using a colony counter (Oxford Optronics, Oxford, United Kingdom). Data shown are calculated from the mean values of three independent experiments.
Ab were: α-PUMA (4976) (NEB Cell Signaling, Frankfurt, Germany); α-Survivin (Novus NB 500-201; Novus Biologicals, Littleton, CO); anti-β-Actin (A2066), α-BIM (B7929), anti-alpha-Tubulin (T5168) (Sigma Aldrich, Munich, Germany); α-BCL-XL (66461A), α-Caspase-8 (9745), -9 (9501) (Pharmingen); cleaved Caspase-3 (9664) (Cell Signaling); α-BAX (sc-20067), α-Caspase-3 (sc-7272/-7148), α-ERB-B2 (sc-284), α-EGFR (sc-81449), α-ERK1/2 (sc-135900), α-STAT3 (sc-482) (Santa Cruz Biotechnology, Heidelberg, Germany). Appropriate HRP-, Cy3- or FITC-conjugated secondary antibodies (Sigma Aldrich, Munich, Germany; Santa Cruz Biotechnology, Heidelberg, Germany) were used.
Preparation of whole lysates from cells or tissue, co-immunoprecipitations and immunoblotting were carried out as described [61, 62]. Equal loading of lysates was controlled by reprobing blots for Actin or Tubulin as described . Immunofluorescence was performed as described in detail [62, 66, 68].
Tissue samples or transfected cell pellets were formalin fixed, paraffin embedded (FFPE) and processed for IHC as described [25, 61]. For antigen retrieval, sections were treated in a pressure cooker with Tris buffer (10 mM, pH9.0) for BIM or were treated with proteinase K (S3020, DakoCytomation, Glostrup, Denmark) for 8 min at room temperature for EGFR detection. Sections were incubated with primary Ab (α-BIM, 1:800; α-EGFR 1:50) overnight at 4°C. For visualization, the EnVision® detection system (Dako GmbH, Hamburg, Germany) was applied as described . Sections were counterstained with hematoxylin. Negative control slides without primary Ab were included for each staining. For quantification, sections were scanned at low power to identify areas of positivity and three random fields were selected. Expression levels for BIM were scored semi-quantitatively based on staining intensity and distribution using the immunoreactive score (IRS) . IRS=SI (staining intensity) × PP (percentage of positive cells). SI is assigned as 0, negative; 1, weak; 2, moderate; 3, strong. PP is defined as 0, negative; 1, <5%; 2, 6–30%; 3, 31–60%; and 4, >60% positive cells.
Assessment of apoptosis was performed by quantifying Caspase-3-dependent hydrolysis of a fluorogenic substrate and by immunoblot-based detection of cleaved caspases . Apoptotic cells were visualized by analyzing mitochondrial integrity using the PromoKine Mitochondrial Apoptosis Staining Kit (PromoCell; Heidelberg, Germany), staining of fragmented nuclei with Hoechst dye or TUNEL-staining as described . Briefly, 200 cells from three separate images were inspected and the percentage of apoptotic cells determined. Cell viability was calculated employing MTT-assays and the electric sensing zone method as described in detail [61, 62]. Cell cycle profiles were obtained by FACS-mediated analysis of prodidium iodide (PI) stained cells as outlined before .
All animal work has been conducted according to relevant national and international guidelines. For animal studies, FaDu cells (2×106) cells were implanted into both flanks of four-week-old female NMRI nu/nu mice (Harlan Winkelmann, Hamburg, Germany) , and were allowed to establish for 7 days followed by treatment for 14 days. VPA/HU (350 mg/kg, 750 mg/kg body weight) or PBS control was administered intraperitoneally (i.p.) every second day as described . Mice were randomized into groups (4 mice/group) such that the average tumor volumes across the groups were equal. Tumor growth was monitored using calipers to calculate tumor volumes according to the formula: length × π width2 × 0.52. Animals were euthanized at the end of the study, and the tumors processed for IHC analysis as described . To assess drug-induced side effects, VPA/HU or PBS treatment was also performed in non-transplanted NMRI nu/nu or eight-week-old female C57BL/6 mice (2 mice/group). All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Mainz.
For all experiments stating p-values, a paired Student's t-test was performed. Unless stated otherwise, p-values represent data obtained from three independent experiments done in triplicate. p-values <0.05 were considered as significant.
The expression construct for human BIMEL, pCDNA4/TO-BIMEL, was described . For expression of a BIMEL-GFP fusion, BIMEL cDNA was PCR amplified and cloned into pc3-GFP (pc3BIMEL-GFP) as stated before . pGL3-luciferase reporter constructs containing the BIM promoter, MYB, E2F or AP1 binding sites were introduced previously . Lentiviral vectors constitutively expressing shRNA directed against BIM or a scrambled control, pHR-THT-BIMshRNA-SFFV-eGFP or pHR-THT-scr_shRNA-SFFV-eGFP, respectively, were reported .
We thank T. Heinzel for invaluable discussions and support, S. Friedel and G. Greiner for excellent technical assistance, I. Behrmann for providing PC3 cells, S.C. Biswas for luciferase-reporter constructs, C. Ploner and G. Häcker for BIM plasmids. Grant support: German Cancer Aid (FKZ102362); Landesprogramm ProExzellenz (PE123-2-1); Head and Neck Cancer Foundation; Novartis-Foundation for Therapeutic Research; Wilhelm-Sander Foundation (Nr. 2010.078.1); Stiftung Rheinland-Pfalz für Innovation; DFG KN973/1-1.
|1.||Lippert BM,Knauer SK,Fetz V,Mann W,Stauber RH. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potentialInt J CancerYear: 200712111697417617794|
|2.||Jemal A,Siegel R,Ward E,Hao Y,Xu J,Thun MJ. Cancer statistics, 2009CA Cancer J ClinYear: 2009592254919474385|
|3.||Forastiere AA,Ang KK,Brizel D,Brockstein BE,Burtness BA,Cmelak AJ,Colevas AD,Dunphy F,Eisele DW,Goepfert H,Hicks WL Jr.,Kies MS,Lydiatt WM,Maghami E,Martins R,McCaffrey T,Mittal BB,Pfister DG,Pinto HA,Posner MR,Ridge JA,Samant S,Schuller DE,Shah JP,Spencer S,Trotti A 3rd,Weber RS,Wolf GT,Worden F. Head and neck cancersJ Natl Compr Canc NetwYear: 200866469518691457|
|4.||Fakhry C,Westra WH,Li S,Cmelak A,Ridge JA,Pinto H,Forastiere A,Gillison ML. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trialJ Natl Cancer InstYear: 2008100261918270337|
|5.||Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancerJ Surg OncolYear: 200897701718493921|
|6.||Argiris A,Karamouzis MV,Raben D,Ferris RL. Head and neck cancerLancetYear: 2008371169570918486742|
|7.||Bonner JA,Harari PM,Giralt J,Azarnia N,Shin DM,Cohen RB,Jones CU,Sur R,Raben D,Jassem J,Ove R,Kies MS,Baselga J,Youssoufian H,Amellal N,Rowinsky EK,Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J MedYear: 20063545677816467544|
|8.||Morris LG,Chan TA. Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancerOncotargetYear: 20112894522248868|
|9.||Blagosklonny MV. How cancer could be cured by 2015Cell CycleYear: 200542697815655345|
|10.||Youle RJ,Strasser A. The BCL-2 protein family: opposing activities that mediate cell deathNat Rev Mol Cell BiolYear: 20089475918097445|
|11.||Hendrickson AW,Meng XW,Kaufmann SH. Anticancer therapy: boosting the bang of BimJ Clin InvestYear: 20081183582418949061|
|12.||Sun Q,Ming L,Thomas SM,Wang Y,Chen ZG,Ferris RL,Grandis JR,Zhang L,Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cellsOncogeneYear: 2009|
|13.||Stauber RH,Mann W,Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potentialCancer ResYear: 2007675999600217616652|
|14.||Bots M,Johnstone RW. Rational combinations using HDAC inhibitorsClin Cancer ResYear: 2009153970719509171|
|15.||Buchwald M,Krämer OH,Heinzel T. HDACi–targets beyond chromatinCancer LettYear: 2009280160719342155|
|16.||Krämer OH,Knauer SK,Zimmermann D,Stauber RH,Heinzel T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosisOncogeneYear: 2008277324017653085|
|17.||Müller S,Krämer OH. Inhibitors of HDACs–effective drugs against cancer?Curr Cancer Drug TargetsYear: 2010102102820201785|
|18.||Sikandar S,Dizon D,Shen X,Li Z,Besterman J,Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signalingOncotargetYear: 2010159660521317455|
|19.||Krämer OH,Göttlicher M,Heinzel T. Histone deacetylase as a therapeutic targetTrends in Endocrinology and MetabolismYear: 20011229430011504668|
|20.||Krämer OH,Zhu P,Ostendorff HP,Golebiewski M,Tiefenbach J,Peters MA,Brill B,Groner B,Bach I,Heinzel T,Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2Embo JYear: 20032234112012840003|
|21.||Spange S,Wagner T,Heinzel T,Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levelsInt J Biochem Cell BiolYear: 2009411859818804549|
|22.||Seiwert TY,Haraf DJ,Cohen EE,Stenson K,Witt ME,Dekker A,Kocherginsky M,Weichselbaum RR,Chen HX,Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancerJ Clin OncolYear: 20082617324118375903|
|23.||Seiwert TY,Salama JK,Vokes EE. The chemoradiation paradigm in head and neck cancerNat Clin Pract OncolYear: 200741567117327856|
|24.||Biswas SC,Shi Y,Sproul A,Greene LA. Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathwaysJ Biol ChemYear: 2007282293687417702754|
|25.||Engels K,Knauer SK,Metzler D,Simf C,Struschka O,Bier C,Mann W,Kovacs AF,Stauber RH. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic markerJ PatholYear: 20072115324017334981|
|26.||Deng J,Shimamura T,Perera S,Carlson NE,Cai D,Shapiro GI,Wong KK,Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrionCancer ResYear: 200767118677518089817|
|27.||Leeman RJ,Lui VW,Grandis JR. STAT3 as a therapeutic target in head and neck cancerExpert Opin Biol TherYear: 200662314116503733|
|28.||Schnaiter A,Stilgenbauer S. Refractory chronic lymphocytic leukemia–new therapeutic strategiesOncotargetYear: 201014728221317446|
|29.||D'Agostino L,Giordano A. NSP 5a3a: a potential novel cancer target in head and neck carcinomaOncotargetYear: 201014233521311098|
|30.||D'Agostino L,Giordano A. A Novel Dual Signaling Axis for NSP 5a3a induced apoptosis in Head and Neck CarcinomaOncotargetYear: 201121055107422170762|
|31.||Schneider G,Krämer OH. NFkappaB/p53 crosstalk-a promising new therapeutic targetBiochim Biophys ActaYear: 201118159010320951769|
|32.||Lane AA,Chabner BA. Histone deacetylase inhibitors in cancer therapyJ Clin OncolYear: 20092754596819826124|
|33.||Ware RE,Aygun B. Advances in the use of hydroxyureaHematology Am Soc Hematol Educ ProgramYear: 200962920008183|
|34.||Bolden JE,Peart MJ,Johnstone RW. Anticancer activities of histone deacetylase inhibitorsNat Rev Drug DiscovYear: 200657698416955068|
|35.||Li Y,Kao GD,Garcia BA,Shabanowitz J,Hunt DF,Qin J,Phelan C,Lazar MA. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activityGenes DevYear: 20062025667916980585|
|36.||Blumenschein GR Jr.,Kies MS,Papadimitrakopoulou VA,Lu C,Kumar AJ,Ricker JL,Chiao JH,Chen C,Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerInvest New DrugsYear: 20082681717960324|
|37.||Prince HM,Bishton MJ,Harrison SJ. Clinical studies of histone deacetylase inhibitorsClin Cancer ResYear: 20091539586919509172|
|38.||Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implicationsClin Cancer ResYear: 20091539475719509170|
|39.||Stephens PJ,McBride DJ,Lin ML,Varela I,Pleasance ED,Simpson JT,Stebbings LA,Leroy C,Edkins S,Mudie LJ,Greenman CD,Jia M,Latimer C,Teague JW,Lau KW,Burton J,Quail MA,Swerdlow H,Churcher C,Natrajan R,Sieuwerts AM,Martens JW,Silver DP,Langerod A,Russnes HE,Foekens JA,Reis-Filho JS,van 't Veer L,Richardson AL,Borresen-Dale AL,Campbell PJ,Futreal PA,Stratton MR. Complex landscapes of somatic rearrangement in human breast cancer genomesNatureYear: 200946210051020033038|
|40.||Atmaca A,Al-Batran SE,Maurer A,Neumann A,Heinzel T,Hentsch B,Schwarz SE,Hövelmann S,Göttlicher M,Knuth A,Jäger E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialBr J CancerYear: 2007971778217579623|
|41.||Bug G,Ritter M,Wassmann B,Schoch C,Heinzel T,Schwarz K,Romanski A,Krämer OH,Kampfmann M,Hoelzer D,Neubauer A,Ruthardt M,Ottmann OG. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaCancerYear: 200510427172516294345|
|42.||Tan TT,Degenhardt K,Nelson DA,Beaudoin B,Nieves-Neira W,Bouillet P,Villunger A,Adams JM,White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapyCancer CellYear: 200572273815766661|
|43.||Chen S,Dai Y,Pei XY,Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1Mol Cell BiolYear: 20092961496919805519|
|44.||Lu WJ,Amatruda JF,Abrams JM. p53 ancestry: gazing through an evolutionary lensNat Rev CancerYear: 200997586219776745|
|45.||Mishra A,Bharti AC,Saluja D,Das BC. Trans-activation and expression patterns of jun and fos / AP-1 super-family proteins in human oral cancerInt J CancerYear: 2009|
|46.||Yogev O,Anzi S,Inoue K,Shaulian E. Induction of transcriptionally active Jun proteins regulates drug-induced senescenceJ Biol ChemYear: 2006281344758316966326|
|47.||Weiss C,Schneider S,Wagner EF,Zhang X,Seto E,Bohmann D. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-JunEmbo JYear: 20032236869512853483|
|48.||Yan J,Hales BF. p38 and c-Jun N-terminal kinase mitogen-activated protein kinase signaling pathways play distinct roles in the response of organogenesis-stage embryos to a teratogenJ Pharmacol Exp TherYear: 20083267647218577701|
|49.||Poeta ML,Manola J,Goldwasser MA,Forastiere A,Benoit N,Califano JA,Ridge JA,Goodwin J,Kenady D,Saunders J,Westra W,Sidransky D,Koch WM. TP53 mutations and survival in squamous-cell carcinoma of the head and neckN Engl J MedYear: 200735725526118094376|
|50.||Gillenwater AM,Zhong M,Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cellsMol Cancer TherYear: 2007629677518025281|
|51.||Cragg MS,Jansen ES,Cook M,Harris C,Strasser A,Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimeticJ Clin InvestYear: 20081183651918949058|
|52.||Ruiz-Godoy RL,Garcia-Cuellar CM,Herrera Gonzalez NE,Suchil BL,Perez-Cardenas E,Sacnchez-Perez Y,Suarez-Roa ML,Meneses A. Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinomaJ Exp Clin Cancer ResYear: 20062573816761621|
|53.||Weber A,Langhanki L,Sommerer F,Markwarth A,Wittekind C,Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neckOncogeneYear: 2003224757912879021|
|54.||Hoellein A,Pickhard A,von Keitz F,Schoeffmann S,Piontek G,Rudelius M,Baumgart A,Wagenpfeil S,Peschel C,Dechow T,Bier H,Keller U. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neckOncotargetYear: 2011259960921865609|
|55.||Wang X,Wang R,Hao MW,Dong K,Wei SH,Lin F,Ren JH,Zhang HZ. The BH3-only protein PUMA is involved in green tea polyphenol-induced apoptosis in colorectal cancer cell linesCancer Biol TherYear: 20087902818367875|
|56.||Shields BJ,Hauser C,Bukczynska PE,Court NW,Tiganis T. DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progressionCancer CellYear: 2008141667918691551|
|57.||Pennock S,Wang Z. A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulationMol Cell BiolYear: 20082830203718316398|
|58.||Zhu P,Huber E,Kiefer F,Göttlicher M. Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosisCell CycleYear: 200431240215477762|
|59.||Li N,Sood S,Wang S,Fang M,Wang P,Sun Z,Yang CS,Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxibClin Cancer ResYear: 20051120899615756036|
|60.||Schrell UM,Rittig MG,Anders M,Kiesewetter F,Marschalek R,Koch UH,Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathwayJ NeurosurgYear: 199786845529126901|
|61.||Fetz V,Bier C,Habtemichael N,Schuon R,Schweitzer A,Kunkel M,Engels K,Kovacs AF,Schneider S,Mann W,Stauber RH,Knauer SK. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivinInt J CancerYear: 200912420334119130609|
|62.||Krämer OH,Knauer SK,Greiner G,Jandt E,Reichardt S,Gührs KH,Stauber RH,Böhmer FD,Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signalingGenes DevYear: 2009232233519171783|
|63.||Brenner JC,Graham MP,Kumar B,Saunders LM,Kupfer R,Lyons RH,Bradford CR,Carey TE. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell linesHead NeckYear: 2010324172619760794|
|64.||Welkoborsky HJ,Jacob R,Riazimand SH,Bernauer HS,Mann WJ. Molecular biologic characteristics of seven new cell lines of squamous cell carcinomas of the head and neck and comparison to fresh tumor tissueOncologyYear: 200365607112837984|
|65.||Ploner C,Rainer J,Niederegger H,Eduardoff M,Villunger A,Geley S,Kofler R. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemiaLeukemiaYear: 200822370718046449|
|66.||Knauer SK,Bier C,Habtemichael N,Stauber RH. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and functionEMBO RepYear: 2006712596517099693|
|67.||Knauer SK,Krämer OH,Knösel T,Engels K,Rodel F,Kovacs AF,Dietmaier W,Klein-Hitpass L,Habtemichael N,Schweitzer A,Brieger J,Rödel C,Mann W,Petersen I,Heinzel T,Stauber RH. Nuclear export is essential for the tumor-promoting activity of survivinFaseb JYear: 2007212071617099069|
|68.||Knauer SK,Bier C,Schlag P,Fritzmann J,Dietmaier W,Rodel F,Klein-Hitpass L,Kovacs AF,Doring C,Hansmann ML,Hofmann WK,Kunkel M,Brochhausen C,Engels K,Lippert BM,Mann W,Stauber RH. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex proteinCell CycleYear: 200761502917582222|
|69.||Stauber RH,Rabenhorst U,Rekik A,Engels K,Bier C,Knauer SK. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signalTrafficYear: 2006714617216984408|
|70.||Zantl N,Weirich G,Zall H,Seiffert BM,Fischer SF,Kirschnek S,Hartmann C,Fritsch RM,Gillissen B,Daniel PT,Hacker G. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistanceOncogeneYear: 20072670384817486061|
Keywords: BH3-only protein, chemotherapy resistance, hydroxyurea, oral cancer, tumor xenograft, valproic acid.
Previous Document: From the field of play to the field of combat: a review of the pharmacological management of concus...
Next Document: Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lip...